We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

288 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $10.7M

47% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 78

42% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 36

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

18% more capital invested

Capital invested by funds: $4.55B → $5.34B (+$797M)

5% more funds holding

Funds holding: 274 → 288 (+14)

Holders
288
Holders Change
+14
Holders Change %
+5.11%
% of All Funds
4.52%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.17%
New
51
Increased
115
Reduced
78
Closed
36
Calls
$16.6M
Puts
$10.7M
Net Calls
+$5.94M
Net Calls Change
-$34M

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.7M
2
Holocene Advisors
Holocene Advisors
New York
+$36.1M
3
Macquarie Group
Macquarie Group
Australia
+$35.4M
4
NIP
Nicholas Investment Partners
California
+$31.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$30.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$207M
2
WA
Wasatch Advisors
Utah
-$62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.1M
4
DM
Deerfield Management
New York
-$39.7M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
KI
251
Kapitalo Investimentos
Brazil
$41.4K +$40.8K +654 New
AP
252
Atwood & Palmer
Missouri
$38K – – –
PP
253
PFS Partners
New Jersey
$32.4K – – –
Lazard Asset Management
254
Lazard Asset Management
New York
$29K +$28.5K +458 New
S
255
SignatureFD
Georgia
$22.2K +$3.74K +60 +21%
Daiwa Securities Group
256
Daiwa Securities Group
Japan
$22K -$2.24K -36 -9%
Carson Wealth (CWM LLC)
257
Carson Wealth (CWM LLC)
Nebraska
$22K +$5.11K +82 +32%
LC
258
Lindbrook Capital
California
$20.5K +$1.93K +31 +11%
LSA
259
Leonteq Securities AG
Switzerland
$19.6K – – –
FDCDDQ
260
Federation des caisses Desjardins du Quebec
Quebec, Canada
$19.3K – – –
WTG
261
West Tower Group
Virginia
$18.6K +$18.3K +293 New
LF
262
Lee Financial
Texas
$16.5K – – –
FHA
263
First Horizon Advisors
Tennessee
$11.7K – – –
PTC
264
Private Trust Company
Ohio
$10.5K -$312 -5 -3%
CI Investments Inc
265
CI Investments Inc
Ontario, Canada
$8K +$7.85K +126 +2,520%
FRA
266
Front Row Advisors
California
$7K – – –
TC
267
Truvestments Capital
Florida
$5.63K – – –
WTA
268
Washington Trust Advisors
Massachusetts
$4.94K – – –
PPC
269
Park Place Capital
Alabama
$4.5K – – –
RCM
270
Raleigh Capital Management
North Carolina
$3.87K +$1.25K +20 +49%
BIA
271
Bell Investment Advisors
California
$2.98K – – –
MPWT
272
MassMutual Private Wealth & Trust
Connecticut
$2.72K – – –
AWM
273
Avior Wealth Management
Nebraska
$2.66K – – –
FFA
274
Farther Finance Advisors
California
$2.28K +$2.24K +36 New
BAM
275
Bellevue Asset Management
Washington
$1.9K – – –
9 10
11
12 13

ITCI Hedge Fund Activity: Q2 2023 in Review

288 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ITCI positions and 36 closed out — a net gain of 15 holders — while 115 added to existing stakes and 78 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.

  • 288 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
  • Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
  • 51 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +15 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.

Based on aggregated 13F filings for Q2 2023.